These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12351610)

  • 41. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
    Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
    [No Abstract]   [Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 46. Herceptin-taxol related hand and foot syndrome.
    Merimsky O; Inbar MJ
    Isr Med Assoc J; 2000 Oct; 2(10):786. PubMed ID: 11344738
    [No Abstract]   [Full Text] [Related]  

  • 47. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trastuzumab in advanced breast cancer--a decade of experience in Germany.
    Jackisch C; Schoenegg W; Reichert D; Welslau M; Selbach J; Harich HD; Tesch H; Wohlfarth T; Eustermann H; Hinke A
    BMC Cancer; 2014 Dec; 14():924. PubMed ID: 25487774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
    Ahluwalia MS; Daw HA
    J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
    [No Abstract]   [Full Text] [Related]  

  • 52. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
    Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
    Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current perspectives for treatment of breast cancer.
    Bunnell C
    Breast Cancer; 2000; 7(4):380-8. PubMed ID: 11114868
    [No Abstract]   [Full Text] [Related]  

  • 55. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
    Mizuno Y; Chin K; Ando N; Oike E
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1293-6. PubMed ID: 16969027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).
    Furtlehner A; Schueller J; Jarisch I; Ostermann E; Czejka M
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):145-50. PubMed ID: 16250250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac dysfunction in the trastuzumab clinical experience.
    Speyer J
    J Clin Oncol; 2002 Mar; 20(5):1156-7. PubMed ID: 11870153
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cytolytic hepatitis and esomeprazole during chemotherapy].
    Capitain O; Lortholary A; Abadie-Lacourtoisie S
    Presse Med; 2005 Oct; 34(17):1235-6. PubMed ID: 16230965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia.
    Fink M
    J Clin Oncol; 2011 Feb; 29(4):e81-2. PubMed ID: 21060025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.